Pharmacists in Keansburg, NJ Accepting Medicare
8 Pharmacists found. Showing 1 - 8
 Howard Shulman, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 199 Main Street, Keansburg, NJ 07734 Phone: 732-787-1414 Fax: 732-787-5642 |
Mr. Umapathi Jagarlamudi, R. PH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 199 Main St, Keansburg Pharmacy, Keansburg, NJ 07734 Phone: 732-787-1414 |
 Rania Rabie Khalifa Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 199 Main St, Keansburg, NJ 07734 Phone: 732-787-1414 |
Dr. Jonathan Art Lee, PHARM.D., R.PH., CCP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 199 Main St, Keansburg, NJ 07734 Phone: 732-787-1414 |
Nirmit Patel, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 Main Street, Keansburg, NJ 07734 Phone: 732-769-5559 |
Ms. Tracy Ann Gazerwitz, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 199 Main St, Keansburg, NJ 07734 Phone: 732-787-1414 |
Mr. Trivikram Kanumuri Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 199 Main St, Keansburg, NJ 07734 Phone: 732-787-1414 |
Sweta Patel Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 Main St, Keansburg, NJ 07734 Phone: 732-769-5550 Fax: 732-769-5549 |
News Archive
WHO study finds Remdesivir and other repurposed drugs ineffective in COVID-19
A large-scale randomized trial has recently been conducted by the World Health Organization (WHO) to evaluate the efficacy of four repurposed antiviral medicines, including Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon, currently used to treat hospitalized coronavirus disease 2019 (COVID-19) patients.
Neuroscientists use brain lesion network mapping to identify anatomical origins of free will
Long the domain of philosophy and religion, free will has also been defined by scientists as a combination of two cognitive processes - the desire to act (or volition) and the sense of responsibility for our actions (or agency.)
Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes
Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.
Annual survey ranks states on health, health care
An annual survey ranks state's overall health and gives snap shots of specific measures including crime, air pollution and smoking rates.
› Verified 5 days ago
Pharmacists
Occupational Therapists
Clinical Social Workers
Dentists